Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | DPP4 | P27487 | 3/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16050342 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2DPP4HSP90AA1CHEK1ALDH1A1 | |
| SCHEMBL17548192 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2DPP4HSP90AA1CHEK1ALDH1A1 | |
| SCHEMBL17436079 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2DPP4HSP90AA1CHEK1ALDH1A1 | |
| SCHEMBL10515631 | 0.80 | DPP4 (0.43) | SMN1; SMN2DPP4ALDH1A1MAPK1RECQL | |
| SCHEMBL10513315 | 0.80 | HSP90AA1 (0.46) | SMN1; SMN2DPP4HSP90AA1ALDH1A1MAPK1 | |
| SCHEMBL6643658 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2DPP4HSP90AA1ALDH1A1MAPK1 | |
| SCHEMBL31347161 | 0.75 | MAPT (0.52) | SMN1; SMN2DPP4CHEK1ALDH1A1MAPK1 | |
| SCHEMBL5791166 | 0.75 | MAPT (0.52) | SMN1; SMN2DPP4CHEK1ALDH1A1MAPK1 | |
| SCHEMBL13622778 | 0.74 | ALDH1A1 (0.44) | HSP90AA1ALDH1A1MAPK1HSD17B10KDM4E | |
| SCHEMBL17887300 | 0.74 | NOS3 (0.45) | SMN1; SMN2HSP90AA1ALDH1A1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970119-B1 | NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | CADILA HEALTHCARE LIMITED (IN) | 2021-09-23 | — | — | US | disclosed |
| CN-112543757-A | Condensed azaheteroaryl compounds having antibacterial activity against tubercle bacillus | 卡迪拉保健有限公司 | 2021-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | DPEP1, SAT1, PEPD | SMN1; SMN2 4576/4885DPP4 35/4885HSP90AA1 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.